Drug Profile
YD 307
Alternative Names: FY-307; YD-307Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator YD Global Life Science
- Developer Hanrim University; YD Global Life Science
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neuropathic-pain(Chemotherapy-induced) in South Korea
- 04 Jul 2016 Preclinical trials in Neuropathic pain (Chemotherapy-induced) in South Korea (unspecified route)